DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES

点击翻译按钮获取中文摘要

Inimmune is developing a second generation synthetic AS01-like adjuvant system (termed SAS), by partnering our novel fully synthetic TLR4 agonist INI-2002, with a semi-synthetic saponin for use in vaccines. Pre-clinically, SAS has demonstrated excellent antibody and T-cell immune responses when paired with a split flu antigen. This versatile vaccine adjuvant is expected to provide a significant enhancement to the immune response to both viral and bacterial vaccines while exhibiting a favorable safety profile. Under this contract, Inimmune, in collaboration with its subcontracting partners, will optimize, scale-up, and produce cGMP SAS in an effort to advance it to an IND submission.